SCHEMBL296751

SCHEMBL296751

CC(CCN1CCC(NCS(C)(=O)=O)CC1)(C(=O)NCc1ccccc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 8/20 0.44
TACR1 P25103 7/20 0.44
TACR2 P21452 2/20 0.44
SIGMAR1 Q99720 2/20 0.43
HRH1 P35367 1/20 0.42
CCR3 P51677 1/20 0.42
KCNH2 Q12809 1/20 0.41
CACNA1I Q9P0X4 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
DRD4 P21917 1/20 0.40
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
BACE1 P56817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298316 0.86 TACR3 (0.46) TACR3TACR1TACR2SIGMAR1HRH1
SCHEMBL296750 0.86 TACR3 (0.51) TACR3TACR1TACR2KCNH2CACNA1I
SCHEMBL8034347 0.85 TACR3 (0.42) TACR3TACR1TACR2SIGMAR1HRH1
SCHEMBL296022 0.83 TACR3 (0.43) TACR3TACR1TACR2SIGMAR1HRH1
SCHEMBL296888 0.83 TACR3 (0.45) TACR3TACR1TACR2SIGMAR1HRH1
SCHEMBL297826 0.83 TACR3 (0.47) TACR3TACR1TACR2SIGMAR1HRH1
SCHEMBL296032 0.82 TACR3 (0.46) TACR3TACR1TACR2SIGMAR1KCNH2
SCHEMBL297584 0.81 TACR3 (0.43) TACR3TACR1TACR2HRH1CCR3
SCHEMBL295621 0.81 TACR3 (0.59) TACR3TACR1TACR2HRH1CCR3
SCHEMBL296164 0.80 PDE5A (0.42) TACR3TACR1TACR2HRH1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200982-B1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-03-14 EP disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 TACR3 95/4885TACR1 26/4885TACR2 21/4885
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 TACR3 95/4885TACR1 26/4885TACR2 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.